TransCode Therapeutics Announces Withdrawal of Registration Statement
06 déc. 2022 16h20 HE
|
TransCode Therapeutics, Inc.
BOSTON, Dec. 06, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (the “Company”), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics,...
TransCode Therapeutics Announces eIND Submission to US FDA for Planned First-in-Human Clinical Trial in Patients with Advanced Solid Tumors
30 nov. 2022 07h00 HE
|
TransCode Therapeutics, Inc.
BOSTON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today...
TransCode Therapeutics Reports Third Quarter 2022 Results; Provides Business Update
14 nov. 2022 16h15 HE
|
TransCode Therapeutics, Inc.
BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported...
TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-siPDL1, in Pancreatic Adenocarcinoma
09 nov. 2022 07h00 HE
|
TransCode Therapeutics, Inc.
BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported...
TransCode Therapeutics to Present at Sidoti Virtual Investor Conference
07 nov. 2022 08h00 HE
|
TransCode Therapeutics, Inc.
BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced...
TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Pancreatic Adenocarcinoma
26 oct. 2022 07h00 HE
|
TransCode Therapeutics, Inc.
BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported...
TransCode Therapeutics Announces Publication of Feline Case Study in Frontiers in Oncology
13 oct. 2022 07h00 HE
|
TransCode Therapeutics, Inc.
BOSTON, Oct. 13, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced...
TransCode Therapeutics to Participate at the Chardan 6th Annual Genetic Medicines Conference
27 sept. 2022 08h00 HE
|
TransCode Therapeutics, Inc.
BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced...
TransCode Therapeutics Appoints MicroRNA Pioneer, Dr. Frank Slack, to its Advisory Board
08 sept. 2022 08h00 HE
|
TransCode Therapeutics, Inc.
BOSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced...
TransCode Therapeutics Reports Second Quarter 2022 Results; Provides Business Update
15 août 2022 16h15 HE
|
TransCode Therapeutics, Inc.
BOSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported...